Overall, these results suggest that targeting claudin-4’s functional effects through CMP and FSK reduces EOC cell survival during olaparib treatment, highlighting claudin-4’s potential to decrease olaparib resistance and promote ovarian cancer cell death. This evidence concerns the gene CLDN4 and ovarian cancer.